Bibli'OSE 2025: A reference Event in Amyloidosis !

We would like to express our deep gratitude to our partners for their essential contribution to the success of this event: the BibliOSE, which offers diligent, interactive and captivating monitoring of amyloidosis news.

The Amyloidosis Network launched Bibli'OSE in 2021 under the guidance of Professors Olivier LAIREZ and Thibaud DAMY as a comprehensive bibliography on amyloidosis. Bibli'OSE features concise 30-minute live online programs where experts present and discuss two scientific publications. These sessions take place every other Thursday from 1:30 p.m. to 2:00 p.m.
This document outlines our strategy, objectives, and the results achieved.

I – Our sevenfold strategy to improve diagnosis

The strategy is sevenfold to improve diagnosis among cardiologists. That is to say that the Bibli'OSE of course makes it possible to inform caregivers of scientific news on amyloidosis, but it also makes it possible to give a permanent booster shot to improve the diagnosis. That is to say that caregivers are constantly stimulated to make the diagnosis. In other words, caregivers are constantly stimulated.

Bibli'OSE
La biblio de l'amylose

1 – Creation of an invested caregivers' community in the disease management. This initiative brings together committed caregivers across the region to improve the diagnosis, monitoring and treatment of patients. It promotes knowledge sharing, exchanges of good practices and continuing training.

2- The participation of a amyloidosis experts community. The Bibli'OSE makes visible these caregivers who invest in all the territory for the care of patients. The impact is direct and facilitates referral of patients to expert centres. Note that the Bibli'OSE is linked to the amyloidosis network website where the care network and the contacts of the different centers are described. **And we welcome, each year, new experts to participate as speakers at Bibli'OSE.**

3 - A first communication by 5 emails to invite to the Bibli'OSE (approximately D-15, D-7, D-3, D-1 and D-Day) before each Bibli'OSE. This makes 110 emails sent each year to remind doctors of the existence of amyloidosis, not counting the emails/newsletter of replays. This communication is carried out by mailing to a network of more than 6,000 French-speaking doctors (cardiologist, neurologist, hematologist)…

4 – The broadcast commented live every other Thursday is available on the following sites:
- Amylose Network YouTube channel: https://www.youtube.com/channel/UCQ0tGX3rnI5h0vaEmB_wnPA
- Platform www.bibliose.org
- Social networks

Live attendees can ask questions in live via the available chat and speakers answer those questions.

5 - Replays are sent to social networks: twitter, facebook, instagram. What contributes to increase the "awareness"

6 – Viewing the replay videos which are made available on the YouTube channel and on the Bibli'OSE platform www.Bibli'OSE.org with also the possibility of finding the videos when searching for keywords and which refers to the youtube channel and the amyloidosis network website, which contains a wealth of information to optimize diagnosis and treatment.

7 - Emails with replays are sent to cardiologists (same listing as for the announcement of sessions). What contributes to increase the "awareness"
In short, the Bibli'OSE has become an essential meeting in the world of amyloidosis which allows this disease to be constantly reminded of caregivers.

8- The implementation of subtitles which allows translation into multiple languages.

II – Bibli'OSE's popularity

Bibli'OSE sessions attract more and more participants :

between 400 and 800 connected to each live.

Concerning the replays available on our Youtube channel, the majority of videos have more than 2000 views and more than 6 000 for the most popular.

On YouTube, BibliOSE continues to demonstrate strong and sustained engagement. In 2025, 40 videos published during the year generated more than 60,000 views and nearly 2,900 hours of watch time, with an average viewing duration of over three minutes per video.

This level of engagement reflects the ongoing attractiveness of BibliOSE as a scientific dissemination tool, supporting continuous learning and long-term access to key publications in amyloidosis. The regular use of playlists further highlights the role of BibliOSE replays as a structured and reusable educational resource for healthcare professionals.

III – BIBLIOSE's speackers

NOM	Prénom	VILLE
ABROUD	Hajer	PARIS
ADDA	Jérôme	BÉZIERS
AGUILHON	Sylvain	MONTPELLIER
AGUILLON	Sylvain	MONTPELLIER
ALAN	Guillaume	MACON
ALGALARRONDO	Vincent	PARIS
ALOS	Benjamin	POITIERS
ANTOINE	Clémence	TOURS
AUDARD	Vincent	CRÉTEIL
BAUDRY	Guillaume	NANCY
BECLE	Clément	LYON
BERTHELOT	Emmanuelle	PARIS
BIERE	Loïc	ANGERS
BISSON	Arnaud	TOURS
BODEZ	Diane	SAINT DENIS
BOITEUX	Marie-Claire	CLERMONT FERRAND
BROUSSIER	Amaury	CRÉTEIL
CARIOU	Eve	TOULOUSE
CLAUSE	Anne-Lorraine	BRUXELLES - BELGIQUE
COLOMBAT	Magali	TOULOUSE
COSTA	Jérôme	REIMS
DAGORN	Joël	BOURGOIN-JALLIEU
DAMY	Thibaud	CRETEIL
DANG	Julien	PARIS
DEEP SINGH CHADAH	Gagan	CRÉTEIL
DELBARRE	Marc-Antoine	AMIENS
DELMAS	Clément	TOULOUSE

DELMOTTE	Thomas	REIMS
DESPORT	Estelle	POITIERS
DEUX	Jean-François	LAUSANNE - SUISSE
DONAL	Erwan	RENNES
DUBOC	Denis	PARIS
DUPARC	Alexandre	TOULOUSE
DURDON	Priscilla	REIMS
EICHER	Jean-Christophe	DIJON
EPAILLY	Eric	STRASBOURG
EYHARTS	Damien	TOULOUSE
FANEN	Pascale	CRÉTEIL
FARRUGIA	Agnès	PARIS
FAUVEL	Charles	ROUEN
FERRAND	Benjamin	DIJON
FLECHER	Erwan	RENNES
FOURNIER	Pauline	TOULOUSE
FRAIX	Antoine	PARIS
FRENKEL	Valérie	CRÉTEIL
GALAT	Arnault	CRETEIL
GALLI	Elena	RENNES
GREEN	Lisa	LYON
GUEFFET	Jean-Pierre	NANTES
GUENANCIA	Charles	DIJON
GUENDOUZ	Soulef	CRETEIL
GUIJARRO	Damien	GRENOBLE
HABIB	Gilbert	MARSEILLE
HEBRARD	Bérénice	CRÉTEIL
HUART	Antoine	TOULOUSE
HUTTIN	Olivier	NANCY
HYAFIL	Fabien	PARIS
INAMO	Jocelyn	FORT DE France - MARTINIQUE
ITTI	Emmanuel	CRÉTEIL
JAVAUGUE	Vincent	POITIERS
JEANNETEAU	Julien	TRELAZE
JOBBE-DUVAL	Antoine	LYON

LAIREZ	Olivier	TOULOUSE
LALOMBARDA	Fabien	CAEN
LEGALLOIS	Damien	CAEN
LEGRAND	Lise	PARIS
LELLOUCHE	Nicolas	CRETEIL
LENESTOUR	Julien	LA ROCHELLE
LEQUEUX	Benoît	POITIERS
LOUNACI	Karima	FORT DE France - MARTINIQUE
LUCAS	Claire	MONTPELLIER
MAAMAR	Mouna	RABAT – MAROC
MARGERIT	Léa	GRENOBLE
MEUNE	Christophe	PARIS
MIKA	Delphine	PARIS
MIRAILLES	Raphael	PARIS
MOHTY	Dania	RIYADH - ARABIE SAOUDITE
MOREAU	Christophe	LA ROCHELLE
MOUQUET	Frédéric	LILLE
NICOL	Martin	PARIS
OBADIA	Jean-François	LYON
OGHINA	Silvia	CRETEIL
PEZEL	Théo	USA
PIERRE	Marine	REIMS
PIRIOU	Nicolas	NANTES
POKU	Nana	GENÈVE
POULEUR	Anne-Catherine	BRUXELLES - BELGIQUE
POULLOT	Elsa	CRÉTEIL
POZZI	Matteo	LYON
PRIGENT	Heloïse	PARIS
PUISSANT	Bénédicte	TOULOUSE
REANT	Patricia	PESSAC
ROUBILLE	François	MONTPELLIER
ROUVIERE	Anne-Sophie	NIMES
SAKHI	Hamza	CRÉTEIL
SALVAT	Muriel	GRENOBLE
SERONDE	Marie-France	BESANÇON

SOUFIANI	Aïda	TEMARA -MAROC
SOULLIER	Camille	NIMES
STEVANT	David	NANTES
TAZI MEZALEK	Zoubida	RABAT - MAROC
TOULZA	Olivier	TOULOUSE
TOURNOUX	François	MONTREAL - QUEBEC
TROISFONTAINES	Pierre	MORTROUX - BELGIQUE
TRUFFIER	Ariane	PARIS
VARNOUS	Shaïda	PARIS
VON HUNOLSTEIN	Jean-Jacques	STRASBOURG
WAHBI	Karim	PARIS
WAJCHERT	Thibaut	PARIS
ZAROUI	Amira	CRETEIL
ZORES	Florian	STRASBOURG

IV -Articles presented during Bibli'OSE sessions

2025						
09-janv	Prognostic implication of DPD quantification in transthyretin cardiac amyloidosis. https://pubmed.ncbi.nlm.nih.gov/39545930/	39545930	Erwan DONAL	Eur Heart J Cardiovasc Imaging .	R Rettl	2024
09-janv	Impact of the Noninvasive Diagnostic Algorithm on Clinical Presentation and Prognosis in Cardiac Amyloidosis. https://pubmed.ncbi.nlm.nih.gov/39290816/	39290816	Jean-Pierre GUEFFET	JACC Adv .	G Tini	2024
30-janv	Single-photon emission computed tomography/computed tomography quantification of Tc-99m pyrophosphate uptake to assess tafamidis treatment response in transthyretin cardiac amyloidosis. https://pubmed.ncbi.nlm.nih.gov/39389529/	39389529	Damien LEGALLOIS	J Nucl Cardiol .	C Godoy-Riv	2024
30-janv	Transthyretin Tetramer Destabilization and Increased Mortality in the General Population. https://pubmed.ncbi.nlm.nih.gov/39630472/	39630472	Antoine JOBBE-DUVAL	JAMA Cardiol .	M Christoffe	2024
13-févr	Effect of Tafamidis on Renal Function in Patients With Transthyretin Amyloid Cardiomyopathy in ATTR-ACT. https://pubmed.ncbi.nlm.nih.gov/38774010/	38774010	Julien DANG	JACC CardioOncol .	B W Sperry	2024
13-févr	Kidney Outcomes in Transthyretin Amyloid Cardiomyopathy. https://pubmed.ncbi.nlm.nih.gov/39550765/	39550765	Hamza SAKHI	JAMA Cardiol .	A Ioannou	2024
20-févr	Amyloidosis and Heart Transplantation in a New Era. https://pubmed.ncbi.nlm.nih.gov/39775986/	39775986	Anne-Catherine POULEUR	Clin Transplant .	MA Lyle	2025
20-févr	Myocardial Inflammation in Cardiac Transthyretin Amyloidosis: Prevalence and Potential Prognostic Implications. https://pubmed.ncbi.nlm.nih.gov/39866106/	39866106	Damien GUIJARRO	Circ Heart Fail .	ML Müller	2025
06-mars	Accuracy of Established Prognostic Staging Systems for Cardiac Transthyretin Amyloidosis in the Tafamidis Era. https://pubmed.ncbi.nlm.nih.gov/39826440/	39826440	Damien EYHARTS	JACC Adv.	M Leo Mülle	2025
06-mars	Clinical Phenotype and Prognosis of Asymptomatic Patients With Transthyretin Cardiac Amyloid Infiltration. https://pubmed.ncbi.nlm.nih.gov/39841451/	39841451	Antoine FRAIX	JAMA Cardiol .	A Porcari	2025
20-mars	Wild-type transthyretin cardiac amyloidosis and aortic stenosis: Can carpal tunnel syndrome help distinguish the chicken from the egg ? https://pubmed.ncbi.nlm.nih.gov/39610264/	39610264	Eve CARIOU	J Intern Med	MA Delbarre	2025
20-mars	Descriptive study of the clinical and myocardial status of a population with anatomopathological aortic valve amyloidosis. https://pubmed.ncbi.nlm.nih.gov/39025343/	39025343	Arnault GALAT	Cardiovasc Pathol .	JB Brette	2024

03-avr	The Mayo ATTR-CM score versus other diagnostic scores and cardiac biomarkers in patients with suspected cardiac amyloidosis. https://pubmed.ncbi.nlm.nih.gov/39252401/	39252401	David STEVANT - CHU de Nantes - Praticien Hospitalier, Spécialiste Insuffisance cardiaque - Cardiomyopathies - Valvulopathies	Eur J Heart Fail .	G Battista Bonfioli	2024
03-avr	Diagnostic value of bone scintigraphy versus CMR in cardiac amyloidosis. https://pubmed.ncbi.nlm.nih.gov/39952470/	39952470	Jean-Christophe EICHER	J Cardiovasc Magn Reson .	J Obergasse	2025
17-avr	Tafamidis in octogenarians with wild-type transthyretin cardiac amyloidosis: an international cohort study. https://pubmed.ncbi.nlm.nih.gov/40036202/	40036202	Emmanuelle BERTHELOT	Eur Heart J .	P Debonnair	2025
17-avr	Response to therapy with tafamidis 61 mg in patients with cardiac transthyretin amyloidosis: real-world experience since approval. https://pubmed.ncbi.nlm.nih.gov/39018203/	39018203	Antoine JOBBE-DUVAL	Amyloid .	Fabian Aus dem Siepen	2024
24-avr	A series of cases of transthyretin amyloid cardiomyopathy with negative bone scintigraphy but a confirmed positive endomyocardial biopsy. https://pubmed.ncbi.nlm.nih.gov/39407234/	39407234	Jean-Pierre GUEFFET	Orphanet J Rare Dis .	A Fraix	2024
24-avr	Impact of Heart Failure Severity on Vutrisiran Efficacy in Transthyretin Amyloidosis with Cardiomyopathy. https://pubmed.ncbi.nlm.nih.gov/40099776/	40099776	Gagan DEEP SINGH	J Am Coll Cardiol .	M S Maurer	2025
15-mai	Efficacy of Acoramidis on All-Cause Mortality and Cardiovascular Hospitalization in Transthyretin Amyloid Cardiomyopathy. https://pubmed.ncbi.nlm.nih.gov/40074465/	40074465	Jean-Jacques VON HUNOL	**J Am Coll Cardiol** .	D P Judge	2025
15-mai	Clinical Phenotype and Prognostic Significance of Frailty in Transthyretin Cardiac Amyloidosis. https://pubmed.ncbi.nlm.nih.gov/40246385/	40246385	François TOURNOUX	**JACC CardioOncol** .	C Fumagalli	2025
05-juin	Predictors of mortality by an artificial intelligence enhanced electrocardiogram model for cardiac amyloidosis. https://pubmed.ncbi.nlm.nih.gov/39215684/	39215684	Benoît LEQUEUX	**ESC Heart Fail** .	J M Amadio	2025
05-juin	Limitations of apical sparing pattern in cardiac amyloidosis: a multicentre echocardiographic study. https://pubmed.ncbi.nlm.nih.gov/38243591/	38243591	Florian ZORES	**Eur Heart J Cardiovasc Imaging** .	J Cotella	2024
19-juin	Renal Response Criteria for Clinical Trials in Amyloid Light Chain Amyloidosis. https://pubmed.ncbi.nlm.nih.gov/39081759/	39081759	Estelle DESPORT	Kidney Int Rep .	N Leung	2024
19-juin	Machine-learning based subgroups of AL amyloidosis and cumulative incidence of mortality and end stage kidney disease. https://pubmed.ncbi.nlm.nih.gov/39257247/	39257247	Antoine HUART	**Am J Hematol** .	S K Anand	2024
03-juil	Early Increase in Serum Transthyretin by Acoramidis Independently Predicts Improved Survival in TTR Amyloid Cardiomyopathy. https://pubmed.ncbi.nlm.nih.gov/40398971/	40398971	Nana POKU	**J Am Coll Cardiol** .	M S Maurer	2025
03-juil	Atrial amyloidosis identified by biopsy in atrial fibrillation: prevalence and clinical presentation. https://pubmed.ncbi.nlm.nih.gov/40392565/	40392565	Vincent ALGALARRONDO	**Eur Heart J** .	K Shinzato	2025

28 aout	Impact of Vutrisiran on CardiacBiomarkers in Patients WithTransthyretin Amyloidosis WithCardiomyopathy From HELIOS-B. https://pubmed.ncbi.nlm.nih.gov/40769675/	40769675	Charles FAUVEL	**J Am Coll Cardiol** .	M S Maurer	2025
28 aout	Evaluating the Performance and Potential Bias of Predictive Models for Detection of Transthyretin Cardiac Amyloidosis. https://pubmed.ncbi.nlm.nih.gov/40616933/	40616933	Guillaume ALAN	**JACC Adv** .	J Hourmozdi	2025
11-sept	Effect of beta-blockade on mortality in patients with cardiac amyloidosis: A systematic review and meta-analysis. https://pubmed.ncbi.nlm.nih.gov/39041492/	39041492	Frédéric MOUQUET	**ESC Heart Fail** .	C S Kwok	2024
11-sept	Risk for Heart Failure and Atrial Fibrillation Across the Lifespan for Carriers of the Amyloidogenic p.V142I TTR Variant. https://pubmed.ncbi.nlm.nih.gov/40698407/	40698407	Damien GUIJARRO	**Circ Genom Precis Med** .	J L Grodin	2025
25-sept	High-Sensitivity Cardiac Troponin I for Risk Stratification in Wild-Type Transthyretin Amyloid Cardiomyopathy. https://pubmed.ncbi.nlm.nih.gov/40371473/	40371473	Joel DAGORN	**Circ Heart Fail** .	L De Michiel	2025
25-sept	Hepatocyte Growth Factor: A Marker of Cardiac Function, Mortality, and Disease Subtype in Cardiac Amyloidosis. https://pubmed.ncbi.nlm.nih.gov/40570404/	40570404	Loïc BIERE	**JACC Adv** .	M Flesvig He	2025
09-oct	Artificial intelligence-enabled electrocardiography and echocardiography to track preclinical progression of transthyretin amyloid cardiomyopathy. https://pubmed.ncbi.nlm.nih.gov/40679604/	40679604	Julien JEANNETEAU	**Eur Heart J** .	E K Oikonon	2025
09-oct	Value of troponin and NT-proBNP to screen for cardiac amyloidosis after carpal tunnel syndrome surgery. https://pubmed.ncbi.nlm.nih.gov/39181411/	39181411	Florian ZORES	**Int J Cardiol** .	N Noory	2024
23-oct	N-glycosylation of monoclonal light chains on routine MASS-FIX testing is a risk factor for MGUS progression. https://pubmed.ncbi.nlm.nih.gov/32594098/	32594098	Hajer ABROUD	**Leukemia** .	A Dispenzie	2020
23-oct	Complete responses in AL amyloidosis are unequal: the impact of free light chain mass spectrometry in AL amyloidosis. https://pubmed.ncbi.nlm.nih.gov/38194690/	38194690	Bénédicte PUISSANT	**Blood** .	J Bomsztyk	2024
06-nov	Echocardiographic Phenotypic Differences Between Light-Chain and Transthyretin Cardiac Amyloid and Relation to Outcome. https://pubmed.ncbi.nlm.nih.gov/40902955/	40902955	Erwan DONAL	**J Am Soc Echocardiogr** .	I Hamza	2025
06-nov	Non-amyloid specific treatment for transthyretin cardiac amyloidosis: a clinical consensus statement of the ESC Heart Failure Association. https://pubmed.ncbi.nlm.nih.gov/41055898/	41055898	Antoine JOBBE-DUVAL	**Eur Heart J** .	P Garcia-Pa	2025
20-nov	Clinical and prognostic significance of central and obstructive apnoeas in patients with transthyretin cardiac amyloidosis. https://pubmed.ncbi.nlm.nih.gov/39308231/	39308231	Damienn LEGALLOIS	**Eur J Prev Cardiol** .	F Gentile	2025
20-nov	Detecting Transthyretin Cardiac Amyloidosis With Artificial Intelligence: A Nonrandomized Clinical Trial. https://pubmed.ncbi.nlm.nih.gov/41213043/	41213043	Gagan DEEP SINGH	**JAMA Cardiol**	S S Jain	2025

V – Sessions 2025

Bili'OSE 2025		
January 9	April 3	August 28
January 30	April 17	September 11
February 13	April 24	September 25
February 20	May 15	October 9
March 6	June 5	October 23
March 20	June 19	November 6
	July 3	November 20

Bibli'OSE
La biblio de l'amylose

The Bibli'OSE top 10

All yeaars combined

BibliOSE replays are part of a long-term dynamic: some sessions now exceed 4,000 to 6,000 views, demonstrating a sustained interest from the medical community in demanding scientific content that is accessible and directly applicable to clinical practice.

Rank	Title	Year	Views
1	*Efficacy of Acoramidis on All Cause Mortality and Cardiovascular Hospitalization in Transthyretin Amyloidosis* https://www.youtube.com/watch?v=8R37l2o4EiA	2025	**6 074**
2	*Clinical Phenotype and Prognostic Significance of Frailty in Transthyretin Cardiac Amyloidosis* https://www.youtube.com/watch?v=djYNjuTnD1Y	2025	**5 253**
3	*Bibli'OSE : Redéfinir l'épidémiologie de l'amylose cardiaque* – Pouleur AC, Aimo A https://www.youtube.com/watch?v=ODEjbmQwU_g	2022	**4 754**
4	*Diagnostic value of bone scintigraphy versus CMR in cardiac amyloidosis* *https://www.youtube.com/watch?v=BNYp19QudJs*	2025	**4 452**
5	*Bibli'OSE : Pronostic de l'amylose cardiaque* – Tournoux F, Martens P https://www.youtube.com/watch?v=X7iC8R6jnXc	2023	**4 309**
6	*Prospective Multicenter Screening With High Sensitivity Cardiac Troponin T for Wild-Type ATTR* https://www.youtube.com/watch?v=S0MJ0wmvcIs	2024	**4 273**
7	*Bibli'OSE : 3 Variantes génétiques associées à l'amylose TTR* – Fanen P, Patel JK https://www.youtube.com/watch?v=yuFFNGrBb1o	2023	**4 171**
8	*Comparison of cardiac involvement, extracardiac manifestations and outcomes between homozygote and heterozygote* https://www.youtube.com/watch?v=RenCD41ZKjU	2024	**4 160**
9	*Premier retour sur HELIOS-B suite à l'ESC – Vutrisiran in ATTR amyloidosis* https://www.youtube.com/watch?v=O9Eq-M5wh7o	2024	**4 147**
10	*Bibli'OSE : Multi-images du phénotype cardiaque des amyloses* – Donal E, Ioannou A https://www.youtube.com/watch?v=8qN7LtvcqP4	2023	**4 121**

This TOP 10 across all years highlights several major lessons

- Recent content (2024–2025) quickly became among the most viewed videos, reflecting strong demand for information on therapeutic innovations and new prognostic stratification tools.
- Older sessions (2022–2023) maintain a consistent audience, confirming the value of these replays as reference resources that are regularly consulted over time.
- The most popular topics include:
    - prognosis,
    - non-invasive diagnosis (scintigraphy, biomarkers),
    - genetics and clinical phenotypes,
    - and structuring therapeutic trials.

These results fully illustrate BibliOSE's role as an interface between research, innovation, and clinical practice, with content that is both immediately useful and enduring.